Delivery of Gefitinib in synergism with Thymoquinone via Transferrin Conjugated Nanoparticle Sensitizes Gefitinib Resistant Non-Small Cell Lung Carcinoma to Control Metastasis and Stemness

2021 ◽  
Author(s):  
Priyanka Upadhyay ◽  
Avijit Ghosh ◽  
Arijita Basu ◽  
P. A. Pranati ◽  
Payal Gupta ◽  
...  
Keyword(s):  
Small Cell Lung Carcinoma ◽  
Growth Factor Receptor ◽  
Signal Transduction Pathway ◽  
Small Cell ◽  
Transduction Pathway ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Cellular Signal ◽  
Cellular Signal Transduction Pathway ◽  
Epidermal Growth

Epidermal growth factor receptor (EGFR) normally over-express in non-small cell lung cancer (NSCLC) and its mutations act as oncogenic drivers in the cellular signal transduction pathway and induce downstream activation...

scholarly journals Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma

Open Medicine ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. 68-77 ◽  
Author(s):  
Yuli Wang ◽  
Zhitao Guo ◽  
Yang Li ◽  
Qinghua Zhou
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Small Cell Lung Carcinoma ◽  
Acquired Resistance ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
T790m Mutation ◽  
Cell Lung Carcinoma ◽  
Epidermal Growth ◽  
Egfr T790m

AbstractIndividualized therapies targeting epidermal growth factor receptor (EGFR) mutations show promises for the treatment of non small-cell lung carcinoma (NSCLC). However, disease progression almost invariably occurs 1 year after tyrosine kinase inhibitor (TKI) treatment. The most prominent mechanism of acquired resistance involves the secondary EGFR mutation, namely EGFR T790M, which accounts for 50%–60% of resistant tumors. A large amount of studies have focused on the development of effective strategies to treat TKI-resistant EGFR T790M mutation in lung tumors. Novel generations of EGFR inhibitors are producing encouraging results in patients with acquired resistance against EGFR T790M mutation. This review will summarize the novel inhibitors, which might overcome resistance against EGFR T790M mutation.

Sign in / Sign up

Export Citation Format

Share Document